Alnylam, Inex, Massachusetts Institute of Technology deal

ALNY received an option to exclusively license worldwide rights to IEX's liposomal drug delivery technology for systemic delivery of RNAi therapeutics. IEX will receive option fees and, if ALNY exercises its option, would be eligible for license fees, milestones and royalties. The companies also partnered to research liposomal formulations for delivering RNAi therapeutics. ...